US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
CA2281224A1
(en)
*
|
1997-02-15 |
1998-08-20 |
Proscript, Inc. |
Treatment of infarcts through inhibition of nf-kappab
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
EP1017398A1
(en)
*
|
1997-09-25 |
2000-07-12 |
Proscript, Inc. |
Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
|
KR100458403B1
(ko)
*
|
1997-09-29 |
2004-11-26 |
포인트 써러퓨틱스, 인크. |
생체외 조혈세포의 자극방법
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
*
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(en)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalent inhibitors of the proteasome
|
CA2347275C
(en)
*
|
1998-10-20 |
2010-03-09 |
Millennium Pharmaceuticals, Inc. |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
*
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
AU2001287399A1
(en)
*
|
2000-08-16 |
2002-02-25 |
University Of Alberta |
Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
PT1326632E
(pt)
*
|
2000-10-12 |
2007-01-31 |
Viromics Gmbh |
Tratamento para o tratamento de infecções por vírus da hepatite
|
US6713446B2
(en)
|
2001-01-25 |
2004-03-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Formulation of boronic acid compounds
|
EP1392355B1
(en)
|
2001-05-21 |
2007-02-14 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
JP4416501B2
(ja)
*
|
2001-05-30 |
2010-02-17 |
ノバルティス アクチエンゲゼルシャフト |
2−{[n−(2−アミノ−3−(ヘテロアリールまたはアリール)プロピオニル)−アミノアシル]−アミノ}−アルキルボロン酸誘導体
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
WO2003033506A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
|
US7524883B2
(en)
|
2002-01-08 |
2009-04-28 |
Eisai R&D Management Co., Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
US20040002479A1
(en)
*
|
2002-03-12 |
2004-01-01 |
Yihan Wang |
Peptide analogues and uses thereof
|
ATE396971T1
(de)
|
2002-03-13 |
2008-06-15 |
Janssen Pharmaceutica Nv |
Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
|
EA007270B1
(ru)
*
|
2002-03-13 |
2006-08-25 |
Янссен Фармацевтика Н.В. |
Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
|
PL213783B1
(pl)
|
2002-03-13 |
2013-05-31 |
Janssen Pharmaceutica Nv |
Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
|
ES2306858T3
(es)
|
2002-03-13 |
2008-11-16 |
Janssen Pharmaceutica Nv |
Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
|
WO2003084551A1
(de)
*
|
2002-04-05 |
2003-10-16 |
Viromics Gmbh |
Mittel zur behandlung von flaviviridae-infektionen
|
US7514579B2
(en)
*
|
2002-06-13 |
2009-04-07 |
Johns Hopkins University |
Boronic chalcone derivatives and uses thereof
|
JP2006506442A
(ja)
*
|
2002-07-09 |
2006-02-23 |
ポイント セラピューティクス, インコーポレイテッド |
ボロプロリン化合物併用療法
|
JP2005539028A
(ja)
*
|
2002-08-14 |
2005-12-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
乳腺炎の処置のためのnf−カッパbインヒビターの使用
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
EP1396269A1
(en)
*
|
2002-09-09 |
2004-03-10 |
Trigen Limited |
Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis
|
US7112572B2
(en)
*
|
2002-09-09 |
2006-09-26 |
Trigen Limited |
Multivalent metal salts of boronic acids
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
PL374700A1
(en)
*
|
2002-09-20 |
2005-10-31 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
EP1581629B1
(en)
|
2002-12-06 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
US20070110785A1
(en)
*
|
2003-07-03 |
2007-05-17 |
Eugene Tedeschi |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
SG148161A1
(en)
*
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
EP1729757A2
(en)
*
|
2004-02-23 |
2006-12-13 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
DK3385267T3
(da)
|
2004-03-30 |
2021-11-01 |
Millennium Pharm Inc |
Syntese af boronestere og syreforbindelser
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
PT1745064E
(pt)
|
2004-04-15 |
2011-03-23 |
Proteolix Inc |
Compostos para a inibição de uma enzima de proteassoma
|
JP5108509B2
(ja)
|
2004-05-10 |
2012-12-26 |
プロテオリックス, インコーポレイテッド |
酵素阻害のための化合物
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
WO2006012395A2
(en)
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Peptidase inhibitors
|
NZ552865A
(en)
|
2004-07-28 |
2009-09-25 |
Janssen Pharmaceutica Nv |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
EP1805208A2
(en)
|
2004-10-20 |
2007-07-11 |
Proteolix, Inc. |
Labeled compounds for proteasome inhibition
|
EP1814913B1
(en)
|
2004-11-05 |
2015-08-19 |
IGM Biosciences, Inc. |
Antibody induced cell membrane wounding
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
US20090036435A1
(en)
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
WO2006081371A2
(en)
*
|
2005-01-27 |
2006-08-03 |
Research Development Foundation |
Combination therapy with triterpenoid compounds and proteasome inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
NZ598441A
(en)
|
2005-02-16 |
2013-07-26 |
Anacor Pharmaceuticals Inc |
Boron-containing small molecules
|
US7589066B2
(en)
*
|
2005-03-11 |
2009-09-15 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
US20060252740A1
(en)
*
|
2005-04-29 |
2006-11-09 |
Johnson Robert G Jr |
Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
|
DK1885710T3
(en)
|
2005-05-18 |
2015-11-23 |
Janssen Pharmaceutica Nv |
SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
PL1888123T3
(pl)
*
|
2005-06-08 |
2013-06-28 |
Janssen Biotech Inc |
Terapia komórkowa chorób degeneracyjnych oka
|
EP1912664A2
(en)
*
|
2005-07-06 |
2008-04-23 |
Biodevelops Pharma Entwicklung GmbH |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(en)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibitors of cancer cell, t-cell and keratinocyte proliferation
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
DK2623113T3
(en)
|
2005-11-09 |
2017-07-17 |
Onyx Therapeutics Inc |
Enzyme inhibition compound
|
US20090221488A1
(en)
*
|
2005-12-08 |
2009-09-03 |
Wood Kenneth W |
Certain Compositions and Methods of Treatment
|
BRPI0621279B1
(pt)
|
2005-12-30 |
2021-07-20 |
Anacor Pharmaceuticals, Inc |
Moléculas pequenas contendo boro
|
ME01060B
(me)
*
|
2006-01-19 |
2012-10-20 |
Janssen Pharmaceutica Nv |
Derivati aminofenila kao novi inhibitori histon deacetilaze
|
JP5137849B2
(ja)
*
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
|
CA2630717C
(en)
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
US8101616B2
(en)
*
|
2006-01-19 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
SI2719388T1
(sl)
|
2006-02-16 |
2019-06-28 |
Anacor Pharmaceuticals, Inc. |
Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
*
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
US7691852B2
(en)
|
2006-06-19 |
2010-04-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
CA2662432A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Janssen Pharmaceutica Nv |
Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
|
AU2007296256B2
(en)
*
|
2006-09-15 |
2013-05-30 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors with combined activity on class-I and class-IIB histone deacetylases in combination with proteasome inhibitors
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
CA2606634A1
(en)
*
|
2006-12-08 |
2008-06-08 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
*
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
*
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
EP2185693B1
(en)
|
2007-07-31 |
2019-07-03 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
AR068332A1
(es)
|
2007-08-03 |
2009-11-11 |
Summit Corp Plc |
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
SI2178888T1
(sl)
*
|
2007-08-06 |
2012-11-30 |
Millennium Pharm Inc |
Proteasomni inhibitorji
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
WO2009036281A2
(en)
*
|
2007-09-12 |
2009-03-19 |
Dr. Reddy's Laboratories Ltd. |
Bortezomib and process for producing same
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
DK2207791T4
(da)
|
2007-10-04 |
2019-10-07 |
Onyx Therapeutics Inc |
Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
EP2229434B1
(en)
*
|
2007-11-27 |
2011-09-07 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
CA2710122A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
CA2959401C
(en)
|
2008-02-21 |
2021-12-07 |
Centocor Ortho Biotech Inc. |
Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
|
EP3246034A1
(en)
|
2008-03-06 |
2017-11-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
WO2009140309A2
(en)
*
|
2008-05-12 |
2009-11-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
SG194349A1
(en)
*
|
2008-06-17 |
2013-11-29 |
Millennium Pharm Inc |
Boronate ester compounds and pharmaceutical compositions thereof
|
EP2310492B1
(en)
|
2008-06-30 |
2015-07-22 |
Janssen Biotech, Inc. |
Differentiation of pluripotent stem cells
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
EP2348863A4
(en)
*
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
*
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
ES2617560T3
(es)
|
2008-10-21 |
2017-06-19 |
Onyx Therapeutics, Inc. |
Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
|
CA2742268C
(en)
|
2008-10-31 |
2020-02-18 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
US9012218B2
(en)
*
|
2008-10-31 |
2015-04-21 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
RU2555538C2
(ru)
|
2008-11-20 |
2015-07-10 |
Сентокор Орто Байотек Инк. |
Культура плюрипотентных стволовых клеток на микроносителях
|
AU2009316583B2
(en)
*
|
2008-11-20 |
2016-04-21 |
Janssen Biotech, Inc. |
Methods and compositions for cell attachment and cultivation on planar substrates
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
AU2009335744A1
(en)
*
|
2008-12-17 |
2010-07-15 |
Anacor Pharmaceuticals, Inc. |
Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
|
EA201170921A1
(ru)
|
2009-01-09 |
2012-01-30 |
Сан Фарма Адвансед Ресёрч Компани Лимитед |
Фармацевтическая композиция
|
EP2399129B1
(en)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
|
BRPI1006189A2
(pt)
|
2009-03-12 |
2020-08-18 |
Genentech Inc |
uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
AU2010229988B9
(en)
|
2009-03-24 |
2015-09-17 |
Janssen Pharmaceutica Nv |
Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
EP2413901A4
(en)
*
|
2009-03-30 |
2015-05-06 |
Cerulean Pharma Inc |
POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
|
CN102458127B
(zh)
*
|
2009-05-27 |
2014-08-27 |
赛福伦公司 |
用于治疗多发性骨髓瘤的联合治疗
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
EP2280016A1
(en)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
|
WO2010146176A2
(en)
|
2009-06-19 |
2010-12-23 |
Lek Pharmaceuticals D.D. |
Process for hydrogenation of halogenoalkenes without dehalogenation
|
EP2270019A1
(en)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
GB2485113B
(en)
|
2009-07-20 |
2016-12-28 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage
|
BR112012001480A2
(pt)
|
2009-07-20 |
2015-09-01 |
Janssen Biotech Inc |
Diferenciação de células-tronco embriônicas humanas
|
CN102482640B
(zh)
*
|
2009-07-20 |
2015-03-11 |
詹森生物科技公司 |
人胚胎干细胞的分化
|
AU2010281439A1
(en)
*
|
2009-07-28 |
2012-03-15 |
Anacor Pharmaceuticals, Inc. |
Trisubstituted boron-containing molecules
|
AP4039A
(en)
*
|
2009-08-14 |
2017-02-28 |
Daitao Chen |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
MX2012002031A
(es)
*
|
2009-08-19 |
2012-07-04 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
|
JP5567136B2
(ja)
|
2009-09-08 |
2014-08-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法
|
WO2011037731A1
(en)
*
|
2009-09-25 |
2011-03-31 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
ES2624644T3
(es)
|
2009-10-01 |
2017-07-17 |
Janssen Pharmaceutica, N.V. |
Inhibidores de proteasoma para el tratamiento de cáncer
|
WO2011049971A1
(en)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011060199A1
(en)
*
|
2009-11-11 |
2011-05-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
EP2498793B1
(en)
|
2009-11-13 |
2019-07-10 |
Onyx Therapeutics, Inc. |
Oprozomib for use in metastasis suppression
|
CA2785300A1
(en)
|
2009-12-22 |
2011-07-21 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
RU2664864C1
(ru)
|
2009-12-23 |
2018-08-23 |
Янссен Байотек, Инк. |
Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы
|
US9150833B2
(en)
|
2009-12-23 |
2015-10-06 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
WO2011109279A2
(en)
*
|
2010-03-01 |
2011-09-09 |
Centocor Ortho Biotech Inc. |
Methods for purifying cells derived from pluripotent stem cells
|
MA34133B1
(fr)
*
|
2010-03-01 |
2013-04-03 |
Onyx Therapeutics Inc |
Composes pour inhibiteurs de l'immunoproteasome
|
RU2529800C2
(ru)
*
|
2010-03-18 |
2014-09-27 |
ИННОФАРМА, Инк. |
Стабильные составы бортезомиба
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8623911B2
(en)
|
2010-03-19 |
2014-01-07 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
EP3187585A1
(en)
|
2010-03-25 |
2017-07-05 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
NZ602622A
(en)
|
2010-03-31 |
2015-01-30 |
Millennium Pharm Inc |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
WO2011136905A2
(en)
|
2010-04-07 |
2011-11-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
EP2560647B1
(en)
|
2010-04-19 |
2016-04-13 |
Niiki Pharma Inc. |
Combination therapy with a proteasome inhibitor and a gallium complex
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
CN102884176B
(zh)
|
2010-05-12 |
2017-09-05 |
詹森生物科技公司 |
人胚胎干细胞的分化
|
AU2011255647A1
(en)
|
2010-05-18 |
2012-11-15 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
PL2611909T3
(pl)
|
2010-08-31 |
2018-05-30 |
Janssen Biotech, Inc |
Zróżnicowanie ludzkich embrionalnych komórek macierzystych
|
PL2611910T3
(pl)
|
2010-08-31 |
2018-06-29 |
Janssen Biotech, Inc |
Różnicowanie ludzkich embrionalnych komórek macierzystych
|
RU2673946C1
(ru)
|
2010-08-31 |
2018-12-03 |
Янссен Байотек, Инк. |
Дифференцирование плюрипотентных стволовых клеток
|
EP2613788B1
(en)
|
2010-09-07 |
2017-06-21 |
Anacor Pharmaceuticals, Inc. |
Benzoxaborole derivatives for treating bacterial infections
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
WO2012047845A1
(en)
|
2010-10-05 |
2012-04-12 |
App Pharmaceuticals |
Bortezomib formulations stabilised with boric
|
WO2012048745A1
(en)
|
2010-10-14 |
2012-04-19 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
ES2611885T3
(es)
|
2011-01-31 |
2017-05-11 |
Novartis Ag |
Derivados heterocíclicos novedosos
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
JP5086497B1
(ja)
|
2011-03-31 |
2012-11-28 |
ナノキャリア株式会社 |
ボロン酸化合物を含有したブロック共重合体を含む医薬組成物
|
DK2691530T3
(en)
|
2011-06-10 |
2018-05-22 |
Univ Oregon Health & Science |
CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
|
WO2012177835A1
(en)
*
|
2011-06-22 |
2012-12-27 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
RS55053B1
(sr)
|
2011-08-11 |
2016-12-30 |
Janssen Pharmaceutica Nv |
Prediktori za lečenje kancera
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
PT2744332T
(pt)
|
2011-08-19 |
2017-01-24 |
Glaxo Group Ltd |
Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
|
PL2753334T3
(pl)
*
|
2011-08-30 |
2022-12-12 |
Trustees Of Tufts College |
Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
CA2853822A1
(en)
|
2011-10-28 |
2013-05-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
PL2771342T3
(pl)
|
2011-10-28 |
2016-11-30 |
|
Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
|
CA2855356A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
EP2776586B1
(en)
|
2011-11-11 |
2018-03-07 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
CN104093768B
(zh)
|
2011-11-17 |
2016-09-21 |
国立大学法人东京大学 |
导入有苯基硼酸基的嵌段共聚物及其使用
|
BR112014015417A8
(pt)
|
2011-12-22 |
2017-07-04 |
Janssen Biotech Inc |
diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US9234048B2
(en)
|
2012-01-18 |
2016-01-12 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
WO2013112601A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
MX363819B
(es)
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
AU2013227219A1
(en)
|
2012-03-02 |
2014-10-23 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
AU2013230020B2
(en)
|
2012-03-07 |
2018-08-09 |
Janssen Biotech, Inc. |
Defined media for expansion and maintenance of pluripotent stem cells
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
SG10201608469RA
(en)
|
2012-05-16 |
2016-11-29 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
CN104334719B
(zh)
|
2012-06-08 |
2018-02-13 |
詹森生物科技公司 |
人胚胎干细胞向胰腺内分泌细胞的分化
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
EP2869820A4
(en)
|
2012-07-09 |
2016-02-17 |
Onyx Therapeutics Inc |
PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
BR112015005343A2
(pt)
*
|
2012-09-11 |
2017-07-04 |
Cipla Ltd |
processo para a preparação de bortezomib, composto, bortezomib ou seu anidrido, e, processo para a preparação de um composto
|
JP6486826B2
(ja)
|
2012-10-01 |
2019-03-20 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
NZ630287A
(en)
|
2012-11-16 |
2016-07-29 |
Shilpa Medicare Ltd |
Crystalline bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
MX2015008578A
(es)
|
2012-12-31 |
2015-09-07 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
MX2015008619A
(es)
|
2012-12-31 |
2016-01-12 |
Janssen Biotech Inc |
Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas.
|
RU2018116647A
(ru)
|
2012-12-31 |
2018-10-24 |
Янссен Байотек, Инк. |
Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
|
PE20160122A1
(es)
|
2013-03-13 |
2016-02-12 |
Forma Therapeutics Inc |
Compuestos nobles y composiciones para la inhibicion de fasn
|
US10023611B2
(en)
|
2013-04-16 |
2018-07-17 |
Cipla Limited |
Process for the preparation of bortezomib mannitol ester
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
CN105705149A
(zh)
|
2013-10-03 |
2016-06-22 |
米伦纽姆医药公司 |
用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3633381A3
(en)
|
2013-12-05 |
2020-07-29 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
CN106132970B
(zh)
|
2014-02-03 |
2020-09-04 |
俄亥俄州创新基金会 |
硼酸酯和其药物制剂
|
EP2910557A1
(en)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
|
EP3141243B1
(en)
|
2014-05-08 |
2020-07-08 |
The University of Tokyo |
Pharmaceutical composition
|
RU2694311C2
(ru)
|
2014-05-16 |
2019-07-11 |
Янссен Байотек, Инк. |
Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках
|
JP2017524652A
(ja)
|
2014-05-20 |
2017-08-31 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
|
EP4180041A1
(en)
|
2014-08-07 |
2023-05-17 |
Mayo Foundation for Medical Education and Research |
Compounds and methods for treating cancer
|
US10253049B2
(en)
*
|
2014-10-01 |
2019-04-09 |
Merck Patent Gmbh |
Boronic acid derivatives
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
JP2018510859A
(ja)
|
2015-03-17 |
2018-04-19 |
レオン−ナノドラッグズ ゲーエムベーハー |
安定化されたボロン酸化合物を含むナノ粒子
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
US10144761B2
(en)
|
2015-06-19 |
2018-12-04 |
Hanlin Scientific Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120836A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Gebrauchsfertige bortezomib-lösung
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
EP3370719A1
(en)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
US11111296B2
(en)
|
2015-12-14 |
2021-09-07 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
DK3472149T3
(da)
|
2016-06-21 |
2023-11-27 |
Orion Ophthalmology LLC |
Heterocykliske prolinamidderivater
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
JP2020500839A
(ja)
|
2016-10-20 |
2020-01-16 |
ファイザー・インク |
ペプチドボロン酸またはボロン酸エステル化合物を有する治療用粒子ならびにその作製および使用方法
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP2020507615A
(ja)
|
2017-02-17 |
2020-03-12 |
フレゼニウス・カビ・オンコロジー・リミテッド |
ボロン酸エステルの調製のための改良プロセス
|
EP3589659A4
(en)
|
2017-02-28 |
2021-03-24 |
Mayo Foundation for Medical Education and Research |
CANCER TREATMENT COMPOUNDS AND METHODS
|
CN117338932A
(zh)
|
2017-08-23 |
2024-01-05 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
BR112020005079A2
(pt)
|
2017-09-14 |
2020-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
tratamento de combinação para câncer
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
SI3710457T1
(sl)
*
|
2017-11-16 |
2023-02-28 |
Principia Biopharma Inc., |
Zaviralci imunoproteasoma
|
US11225493B2
(en)
|
2017-11-16 |
2022-01-18 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3746065A4
(en)
|
2018-01-29 |
2022-02-16 |
Cognos Therapeutics Inc. |
INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
|
TW202003553A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療癌症之abbv-621與抗癌劑之組合
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
CN113382633A
(zh)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
(4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
JP2023553011A
(ja)
*
|
2020-12-02 |
2023-12-20 |
ホフマン・テクノロジーズ・エルエルシー |
非ヒト哺乳動物においてがんを調節するための組成物および方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
US20230062279A1
(en)
|
2021-08-12 |
2023-03-02 |
Extrovis Ag |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|